GL Ventures, Temasek co-lead $230m round in China's Clover Biopharmaceuticals

GL Ventures, Temasek co-lead $230m round in China's Clover Biopharmaceuticals

Photo: National Cancer Institute/Unsplash

Clover Biopharmaceuticals, a global clinical-stage biotech company that develops and commercialises transformative biologic therapies, announced on Tuesday the completion of an oversubscribed Series C funding round at $230 million.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter